Goel Peeyush N, Gude Rajiv P
Gude Lab, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, Kharghar, Navi Mumbai 410210, Maharashtra, India.
Biomed Pharmacother. 2014 Mar;68(2):191-200. doi: 10.1016/j.biopha.2013.11.003. Epub 2013 Dec 2.
Breast cancer remains the second most prevalent cancer worldwide. Several anticancer drugs are being currently used in the treatment of breast cancer. However, owing to high cytotoxicity, induced resistance and cost ineffectiveness, there is an urgent need to develop newer therapeutic regimens that limit the current problems. One of the approaches in this regard is the formulation of combination therapies whereby multiple drugs are being delivered at relatively lesser dose that surely confines the aforesaid problems. In this purview, we had evaluated the effects of pentoxifylline, a methylxanthine derivative and liposomal doxorubicin (Lipodox), an anthracycline in combination to evaluate their anti-metastatic activities both in vitro and in vivo against breast cancer cells. The combination regime exhibited synergistic activity and inhibited cellular proliferation to a greater extent with regard to each drug used alone.
乳腺癌仍然是全球第二大常见癌症。目前有几种抗癌药物用于治疗乳腺癌。然而，由于高细胞毒性、诱导耐药性和成本效益不佳，迫切需要开发新的治疗方案来解决当前存在的问题。在这方面的一种方法是制定联合疗法，即使用相对较低剂量的多种药物，这肯定能解决上述问题。在这个范围内，我们评估了甲基黄嘌呤衍生物己酮可可碱和蒽环类药物脂质体阿霉素（Lipodox）联合使用的效果，以评估它们在体外和体内对乳腺癌细胞的抗转移活性。联合用药方案表现出协同活性，与单独使用每种药物相比，在更大程度上抑制了细胞增殖。
